Medical Journals

  • Publications

    과학적 근거를 바탕으로
    AI를 설계합니다.

  • Oncology

    Tumor-infiltrating lymphocyte enrichment predicted by CT radiomic analysis is associated with clinical outcomes of immune checkpoint inhibitor in non-small cell lung cancer

    ASCO(2022) — May 27, 2022

    Changhee Park et al.

  • Oncology

    Artificial intelligence (AI)-powered pathology image analysis merged with spatial transcriptomics reveals distinct TIGIT expression in the immune-excluded tumor-infiltrating lymphocytes

    ASCO(2022) — May 27, 2022

    Gahee Park et al.

  • Oncology

    Artificial intelligence-powered human epidermal growth factor receptor 2 (HER2) analyzer in breast cancer as an assistance tool for pathologists to reduce interobserver variation

    ASCO(2022) — May 27, 2022

    Minsun Jung et al.

  • Oncology

    Observer Performance Study to Examine the Feasibility of the AI-powered PD-L1 Analyzer to Assist Pathologists’ Assessment of PD-L1 Expression Using Tumor Proportion Score in Non-Small Cell Lung Cancer

    ASCO(2022) — May 27, 2022

    Seokhwi Kim et al.


업계를 선도하는
글로벌 리더들과
연구 파트너십을
체결합니다.


루닛의 의학 연구 결과를 확인하세요.

All
AI
Breast
Chest
  • Oncology

    Need of pretreatment support of breast cancer patient caregivers compared to patients.

    ASCO(2022) — May 27, 2022

    Terri Kim et al.

  • Oncology

    Robust artificial intelligence-powered imaging biomarker based on mammography for risk prediction of breast cancer.

    ASCO(2022) — May 27, 2022

    Eun Kyung Park et al.

  • Oncology

    Safety and efficacy of YBL-006, an anti-PD-1 monoclonal antibody in advanced solid tumors: a phase I study

    ASCO(2022) — May 27, 2022

    Do-Youn Oh et al.

  • Oncology

    Tumor-infiltrating lymphocyte enrichment predicted by CT radiomic analysis is associated with clinical outcomes of immune checkpoint inhibitor in non-small cell lung cancer

    ASCO(2022) — May 27, 2022

    Changhee Park et al.

  • Oncology

    The Inflamed Immune Phenotype (IIP): a clinically actionable artificial intelligence (AI)-based biomarker predictive of immune checkpoint inhibitor (ICI) outcomes across >16 primary tumor types

    ASCO(2022) — May 27, 2022

    Jeanne Shen et al.

  • Oncology

    Trastuzumab plus FOLFOX for Gemcitabine/Cisplatin refractory HER2-positive biliary tract cancer: a multi-institutional phase II trial of the Korean Cancer Study Group (KCSG-HB19-14)

    ASCO(2022) — May 27, 2022

    Choong-kun Lee et al.

  • Oncology

    Artificial intelligence (AI)-powered pathology image analysis merged with spatial transcriptomics reveals distinct TIGIT expression in the immune-excluded tumor-infiltrating lymphocytes

    ASCO(2022) — May 27, 2022

    Gahee Park et al.

  • Oncology

    Artificial Intelligence (AI) - powered spatial analysis of tumor-infiltrating lymphocytes (TIL) for prediction of response to neoadjuvant chemotherapy (NAC) in triple negative breast cancer (TNBC)

    ASCO(2022) — May 27, 2022

    Hee Jin Lee et al.